Molecules that influence pathogen resistance

• US 20030017985A1
• Filed: 07/02/2002
• Published: 01/23/2003
• Est. Priority Date: 07/02/2002
• Status: Abandoned Application

• Current Assignee: The United States of America As Represented By The Secretary of Agriculture
• Original Assignee: The United States of America As Represented By The Secretary of Agriculture
• Inventors: Taylor, Gregory Alan, Vande Woude, George F.
• Application Number:
  US10/169,315
• Publication Number:
  US 20030017985A1
• Time in Patent Office: Days
• US Class Current: 514/12
• CPC Class Codes: A01K 2217/075 inducing loss of function, i.e. knock out
• CPC Class Codes: A61K 2039/55516 Proteins; Peptides
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: C12N 9/16 acting on ester bonds (3.1)
• CPC Class Codes: C12Y 306/05 acting on GTP; involved in cellular and subcellular movement (3.6.5)
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The functions of IFNγ-induced GTPases of the IGTP-family as strong anti-infective agents, and more particularly a strong anti-parasite and/or anti-bacterial agents, are disclosed. These molecules (in both protein and nucleic acid forms) are effective to modify anti-microbial e.g., anti-bacterial and/or anti-parasitic) immune responses in a subject, to prevent or inhibit replication or infectivity of microbe, to treat microbial diseases, and to detect susceptibility of a subject to microbial infection. This invention also provides kits and compounds useful in such methods. Also provided are transgenic non-human animals in which IGTP-family member gene expression has been altered, and the use of such animals to screen for anti-microbial agents.

Claims

1. A method of modifying an anti-microbial immune response in a subject, comprising modifying an IGIP-family protein activity in the subject to enhance or inhibit the immune response.

2. The method of claim 1, wherein modifying the IGTP-family protein activity comprises altering expression of at least one IGTP-family protein.

3. The method of claim 1, wherein modifying the IGTP-family protein activity comprises supplying the subject with exogenous IGTP-family protein, or a fragment, variant, analog, derivative or mimetic thereof that maintains immune response modifying activity, or with a nucleic acid that encodes the IGTP-family protein, fragment, variant, analog, derivative or mimetic thereof.

4. The method of claim 3, wherein the subject is an animal infected with a bacterial or parasitic disease, or at risk for infection with a bacterial or parasitic disease.

5. The method of claim 1, wherein modifying the IGTP-family protein activity comprises decreasing tissue concentration of an IGTP-family protein in the subject.

6. The method of claim 1, wherein the anti-microbial immune response is a Th1 immune response.

7. The method of claim 1, wherein the anti-microbial immune response is an immune response to a bacterial, protozoa or helminth infection.

8. The method of claim 7, wherein the protozoa comprises Toxoplasma gondii.

9. The method of claim 1, wherein modifying the immune response comprises enhancing the immune response.

10. The method of claim 1, wherein modifying the immune response comprises inhibiting the immune response.

11. The method of claim 1, wherein modifying the immune response is effective to treat or prevent a disease caused by a bacteria or a parasite.

12. The method of claim 1 wherein the animal is a human.

13. The method of claim 12, wherein the anti-microbial response is an anti-parasitic response.

14. The method of claim 15 wherein the animal is a human infected with an organism selected from the group consisting of Toxoplasma sp., Plasmodium sp., Tryapanosoma sp., Leishmania sp., Cryptosporidium sp., Giardia sp., Entamoeba sp., Trichomonas sp., Diphyllobothriun latum, Echinococcosis sp., Schistosoma sp., Wuchereria bancrofti, Brugia malayi and Oncliocerca volvulus.

15. The method of claim 12, wherein the anti-microbial response is an anti-bacterial response.

16. The method of claim 15 wherein the animal is a human infected with an organism selected from the group consisting of Streptococcus sp., Haemophilus influenzae, Klebsiella sp., Escherichia sp., Legionella sp., Mycoplasma sp., Pneumocystis carinii, Listeria, Corynebacterium sp., Staphylococcus sp., Serratia, Pseudomonas, Shigella, Vibrio, Hemophilus sp., Yersinia, Enterobacter, Mycobacteria, Chlamydiae, and rickettsiae organisms.

17. The method of claim 2, wherein IGTP-family protein expression is altered by expressing in the subject a recombinant genetic construct comprising a promoter operably linked to a nucleic acid molecule, wherein the nucleic acid molecule comprises at least 10 consecutive nucleotides of a nucleotide sequence that encodes the IGTP-family protein, and expression of the nucleic acid molecule changes expression of the IGTP-family protein.

18. The method of claim 17 wherein expressing the recombinant genetic construct increases the IGTP-family protein expression.

19. The method of claim 1, wherein the method comprises inhibiting replication or infectivity of an infectious agent in a subject, or treating or preventing infection of the subject by the infectious agent, comprising administering to the subject an amount of IGTP-family protein or encoding sequence, or a fragment, variant, analog or mimetic thereof, sufficient to inhibit infectious agent replication or infectivity.

20. The method of claim 19, wherein the infectious agent is a bacterium.

21. The method of claim 19, wherein the infectious agent is a parasite.

22. The method of claim 21, wherein the parasite is chosen from the group consisting of helminth organisms and protozoan organisms.

23. The method of claim 22, wherein the parasite is a protozoa.

24. The method of claim 23, wherein the parasite is T. gondii.

25. The method of claim 1, wherein the method comprises providing enhanced immunogenicity of an antigen which evokes an immune response, comprising administering to a subject the antigen and an IGTP-family protein, or a fragment, variant, analog or mimetic thereof.

26. The method of claim 25, wherein the antigen is a bacterial antigen.

27. The method of claim 25, wherein the antigen is a protozoan antigen.

28. The method of claim 25, wherein the antigen is a Toxoplasma antigen.

29. The method of claim 1, wherein the method comprises stimulating an immune response to an anti-microbial immunogen, comprising co-administering with the immunogen an adjuvant effective amount of an IGTP-family protein, or a fragment, variant, analog or mimetic thereof, which retains IGTP-family protein adjuvant activity.

30. The method of claim 29, comprising co-administering the IGTP-family protein variant with the immunogen.

31. The method of claim 29, wherein co-administering IGTP-family protein, or the fragment, variant, analog or mimetic thereof, enhances the immune response beyond that achieved by administration of the anti-microbial immunogen alone.

32. The method of claim 1, wherein the method comprises detecting susceptibility of a subject to microbial infection, comprising detecting abnormal IGTP-family protein, abnormal IGTP-family protein expression, or abnormal IGTP-family protein-encoding nucleic acid in the subject.

33. The method of claim 32, wherein detecting abnormal IGTP-family protein expression in a subject comprises detecting an abnormally low level of IGTP, LRG-47, and/or IRG-47 in the subject.

34. The method of claim 32, wherein detecting abnormal IGTP-family protein expression in a subject comprises binding an oligonucleotide to an IGTP-family protein encoding sequence from the subject.

35. The method of claim 34, wherein the oligonucleotide comprises at least 10 consecutive nucleotides from the nucleic acid sequence of GenBank Accession Number U53219, M63630, or U19119.

36. The method of claim 32, wherein detecting abnormal IGTP expression in a subject comprises detecting an IGTP-family protein from the subject with an IGTP-family protein-specific protein binding agent.

37. The method of claim 36, wherein the binding agent is an antibody.

38. A kit for use with the method of claims 32-37, comprising at least one IGTP-family protein specific protein binding agent.

39. The kit of claim 38, wherein the binding agent is an IGTP-specific antibody, and LRG-47-specific antibody, or an IRG-47-specific antibody.

40. A kit for use with the method of claim 32-37, comprising at least one IGTP-family protein encoding nucleic acid specific binding agent.

41. The kit of claim 40, wherein the agent comprises at least 10 nucleotides from the nucleic acid sequence of GenBank Accession Number U53219, M63630, or U19119.

42. The kit of claim 40, wherein the binding agent is capable of specifically binding to at least a portion of

(a) the nucleic acid sequence of GenBank Accession Number U53219, M63630, or U19119;

(b) nucleic acid sequences that differ from those specified in (a) by one or more conservative amino acid substitutions;

or

(c) nucleic acid sequences having at least 80% sequence identity to the sequences specified in (a) or (b).

43. A transgenic non-human animal in which IGTP-family member gene expression has been altered.

44. The transgenic non-human animal according to claim 43, wherein the IGTP-family member is IGTP, LRG-47, or IRG-47.

45. The transgenic non-human animal according to claim 43, wherein IGTP-family member is over-expressed relative to expression prior to IGTP-family member gene expression alteration.

46. The transgenic non-human animal according to claim 43, wherein IGTP-family member is under-expressed relative to expression prior to IGTP-family member gene expression alteration.

47. A method of screening for an anti-microbial compound, comprising administering a candidate compound to the transgenic animal of claim 43.

48. The method of claim 47, wherein the anti-microbial compound is an anti-bacterial compound.

49. The method of claim 47, wherein the anti-microbial compound is an anti-parasitic compound.

50. The method of claim 47, wherein the candidate compound comprises an anti-microbial drug.

51. The method of claim 48, wherein the anti-microbial drug is an analog of a recognized anti-protozoan or anti-bacterial drug.

52. A pharmaceutical composition comprising:

a pharmaceutically acceptable vehicle or carrier

a therapeutically effective amount of at least one anti-microbial compound; and

a therapeutically effective amount of at least one IGTP-family protein, or a fragment, variant, analog or mimetic thereof, or a nucleic acid that encodes an IGTP-family protein, fragment, variant, analog, derivative mimetic thereof.

53. The pharmaceutical composition of claim 52, wherein the anti-microbial compound is an anti-bacterial compound.

54. The pharmaceutical composition of claim 53, wherein the anti-bacterial compound is a bacterial antigen that evokes an immunogenic response to the bacterium.

55. The pharmaceutical composition of claim 52, wherein the anti-microbial compound is an anti-protozoan compound.

56. The pharmaceutical composition of claim 55, wherein the anti-protozoan compound is a protozoan antigen that evokes an immunogenic response to the protozoan.

57. The pharmaceutical composition of claim 52, wherein the anti-protozoan compound is an anti-microbial pharmaceutical compound.

58. The pharmaceutical composition of claim 57, wherein the anti-microbial pharmaceutical compound is a pharmaceutical compound effective in treating or preventing a Toxoplasma infection.

59. The pharmaceutical composition of claim 57, wherein the pharmaceutical compound is selected from the group consisting of pyrimethamine and a sulfonamide, or mixtures thereof.

60. The pharmaceutical composition of claim 59, wherein the sulfonamide is selected from the group consisting of sulfamerazine, sulfadiazine, suflasoxazole, sulfamethazine, and sulfadiazine, or mixtures thereof.

61. A kit comprising the pharmaceutical composition of any one of claims 52-60.